LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

18.44 -0.81

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.13

Max

18.56

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-607K -51M
Pardavimai	-28M 100M
Pelnas, tenkantis vienai akcijai	-0.46
Pelno marža	-51.215
Darbuotojai	1,784
EBITDA	4.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+74.1% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-294M 2.1B
Ankstesnė atidarymo kaina	19.25
Ankstesnė uždarymo kaina	18.44

Naujienos nuotaikos

By Acuity

30%

70%

71 / 344 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-26 16:52; UTC

Svarbiausios naujienos

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q Rev $1.76B >SQM

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q EPS $1.28 >SQM

2026-05-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q EPS $11.61 >WEBC

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q Sales $179.6M >WEBC

2026-05-26 21:48; UTC

Rinkos pokalbiai

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026-05-26 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-05-26 20:58; UTC

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026-05-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 19:22; UTC

Rinkos pokalbiai

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026-05-26 19:17; UTC

Rinkos pokalbiai

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026-05-26 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026-05-26 18:03; UTC

Rinkos pokalbiai

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026-05-26 17:42; UTC

Rinkos pokalbiai

Grains Await Fresh Trading Catalyst -- Market Talk

2026-05-26 17:33; UTC

Rinkos pokalbiai

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026-05-26 17:21; UTC

Rinkos pokalbiai

Canada Faces a Labor Market Squeeze -- Market Talk

2026-05-26 16:52; UTC

Rinkos pokalbiai

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026-05-26 16:43; UTC

Rinkos pokalbiai

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026-05-26 16:24; UTC

Rinkos pokalbiai

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026-05-26 16:21; UTC

Rinkos pokalbiai

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-05-26 16:16; UTC

Rinkos pokalbiai

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026-05-26 16:01; UTC

Rinkos pokalbiai

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026-05-26 15:21; UTC

Rinkos pokalbiai

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

74.1% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD 74.1%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

71 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.